Literature DB >> 11091297

Use of intravenous valproate sodium in status migraine.

J Norton1.   

Abstract

Patients with migraines have typically been given one group of medications for abortive treatment and another for preventative. In the acute situation when the patient has severe nausea it is difficult to administer medications. Intravenous medications would avoid this problem but are limited to the opiates and dihydroergotamine. The following cases demonstrate the acute treatment of migraine with intravenous valproic acid (Depacon). The oral form of valproic acid has been used as a prophylactic agent, but the intravenous form may provide an alternative for abortive care as well. The ease of administration and lack of side effects are also important considerations. Double-blind studies will help clarify the situation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091297     DOI: 10.1046/j.1526-4610.2000.00133.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  6 in total

Review 1.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

2.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07

3.  Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial.

Authors:  Shahir Mazaheri; Jalal Poorolajal; Akram Hosseinzadeh; Mohammad Mahdi Fazlian
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

4.  Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.

Authors:  Clinton Lauritsen; Santiago Mazuera; Richard B Lipton; Sait Ashina
Journal:  J Headache Pain       Date:  2016-11-22       Impact factor: 7.277

5.  Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder.

Authors:  Mohsen Foroughipour; Kavian Ghandehari; Mojtaba Khazaei; Fahimeh Ahmadi; Keyvan Shariatinezhad; Kosar Ghandehari
Journal:  Iran J Med Sci       Date:  2013-06

6.  Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial.

Authors:  Narges Karimi; Mahdiye Tavakoli; Jamshid Yazdani Charati; Mastoureh Shamsizade
Journal:  Clin Exp Emerg Med       Date:  2017-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.